Brief: Ipsen Receives Positive CHMP Opinion For Ojemda
27/02/2026 11:38
Feb 27 (Reuters) - Ipsen SA IPN.PA: IPSEN RECEIVES POSITIVE CHMP OPINION FOR OJEMDA® FOR THE TREATMENT AS MONOTHERAPY OF CHILDREN WITH RELAPSED OR REFRACTORY BRAF-ALTERED PEDIATRIC LOW-GRADE GLIOMA Source text: ID:nGNXcgLHmc Further company coverage: IPN.PA ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ipsen SA
See all newsHealth Rounds: New blood test matches gold standard for liver disease diagnosis
Brief: Ipsen Late-Breaking Data Raises Ambitions In PBC
Brief: Charles River Laboratories International Virtual Control Group To Be Used In Glp Study For Ipsen
Pharming shares rise after preliminary Q3 revenue beat
France's Ipsen Q3 sales rise 28% driven by core portfolio